Dr. Trevor Martin, Ph.D. — Co-Founder & CEO, Mammoth Biosciences
Most of us think of medicine as something we take every day — a statin, a blood pressure pill, or perhaps a monthly injection. But what if those lifelong treatments eventually become obsolete? What if one carefully targeted gene edit could dramatically reduce your risk of heart disease for decades?
Dr. Trevor Martin, Ph.D. is the Co-Founder and Chief Executive Officer of Mammoth Biosciences (https://mammoth.bio/), a pioneering biotechnology company developing next-generation CRISPR genome editing technologies for potentially curative medicines. He co-founded the company in 2017 alongside Nobel Prize-winning CRISPR pioneer Dr. Jennifer Doudna and an interdisciplinary team of leading scientists with the goal of building more precise, versatile, and clinically practical gene editing systems.
Dr. Martin earned his undergraduate degree in Molecular Biology with honors from Princeton University before completing a Ph.D. in Genetics and Statistics at Stanford University, where his research focused on quantitative genetics, genomics, and computational biology. His scientific background in statistics and genetics has shaped Mammoth’s unique approach to developing smaller CRISPR enzymes capable of reaching tissues and diseases that have been difficult to target with first-generation technologies.
Under Dr. Martin’s leadership, Mammoth has grown into one of the world’s leading CRISPR companies, raising more than $465 million, achieving a valuation exceeding $1 billion, and establishing strategic collaborations with companies including Vertex Pharmaceuticals, Bayer, and Regeneron Pharmaceuticals.
Today, Mammoth is advancing a pipeline of in vivo gene editing therapies, including programs targeting cardiovascular disease through permanent editing of the APOC3 gene — a potential one-time treatment approach aimed at dramatically reducing triglycerides and long-term cardiovascular risk. Beyond therapeutics, the company’s CRISPR platform also extends into diagnostics and genome engineering technologies that may reshape medicine over the coming decades.
Dr. Martin has been recognized as an EY Entrepreneur of the Year®, Forbes 30 Under 30, and Fortune 40 Under 40 honoree for his contributions to biotechnology and scientific entrepreneurship.
#CRISPR #GeneEditing #TrevorMartin #MammothBiosciences #JenniferDoudna #Biotechnology #GenomeEditing #HeartDisease #Longevity #FutureOfMedicine #PrecisionMedicine #Genetics #DNA #HealthInnovation #MedicalBreakthrough #CardiovascularDisease #SciencePodcast #Biotech #Innovation #ProgressPotentialPossibilities